Clinical Trials
28 trialsNCT06564844 2026-05-22
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT03456076 2026-05-05
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02486718 2026-04-30
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT03191786 2024-10-23
IPSOS
Hoffmann-La Roche
Phase 3 Completed
NCT05487391 2024-10-15
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02448797 2021-07-20
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT00054197 2020-10-05
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02619929 2018-08-29
StepUp
Pierre Fabre Pharma GmbH
Completed
NCT00455572 2017-05-15
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT00842712 2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00496275 2016-08-26
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
Sanofi
Phase 1 Completed
NCT00686959 2016-06-28
PROCLAIM
Eli Lilly and Company
Phase 3 Completed
NCT01109524 2015-12-24
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01196078 2015-07-27
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01843647 2015-07-15
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT00148798 2014-06-25
FLEX
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00055887 2013-05-10
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Withdrawn
NCT00042315 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated
NCT00432562 2012-02-23
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
Mast Therapeutics, Inc.
Phase 1 Completed
NCT00271271 2009-12-07
GON
Sanofi
Phase 2 Completed
NCT00256711 2009-04-23
Phase II Iressa Versus Vinorelbine (INVITE)
AstraZeneca
Phase 2 Completed
NCT00333294 2007-12-19
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
AstraZeneca
Phase 2 Completed